ArticleJTO clinical and research reports2023

Imaging-Based Biomarkers Predict Programmed Death-Ligand 1 and Survival Outcomes in Advanced NSCLC Treated With Nivolumab and Pembrolizumab: A Multi-Institutional Study.

Sevinj Yolchuyeva et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.